MedPath

The novel EBV biomarkers for prediction of refractory nasal polyposis after functional endoscopic sinus surgery

Conditions
asal polyposis patients who were required to surgery.
Nasal polyp, Endoscopic sinus surgery, EBV, recurrence, refractory
Registration Number
TCTR20220131002
Lead Sponsor
Fundamental Fund
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending (Not yet recruiting)
Sex
All
Target Recruitment
96
Inclusion Criteria

nasal polyposis patients who were scheduled for FESS

Exclusion Criteria

1.patients who received systemic steroids before surgery 4 weeks
2.patients with antrochoanal
3.allergic fungal sinusitis patients
4.patients with nasal and nasopharyngeal tumor
5.patients with autoimmune disease or received immunotherapy
6.patients received chemotherapy and/or radiotherapy in the head and neck field

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
recurrent nasal polyp at 1 week, 1 mo, 3mo,6 mo, 9 mo,12 mo,15 mo, 18 mo Lund Kenedy score
Secondary Outcome Measures
NameTimeMethod
clinical post surgery at 1 wk, 1 mo, 3 mo, 6mo, 9 mo,12mo,15mo,18 mo SNOT 22
© Copyright 2025. All Rights Reserved by MedPath